cathepsin

(redirected from Cathepsin S)
Also found in: Dictionary, Medical.
Related to Cathepsin S: Cathepsin L

cathepsin

[kə′thep·sən]
(biochemistry)
Any of several proteolytic enzymes occurring in animal tissue that hydrolyze high-molecular-weight proteins to proteoses and peptones.
References in periodicals archive ?
The report provides comprehensive information on the Cathepsin S (EC 3.
We hypothesized that plasma concentrations of cathepsin S and cystatin C would differ between COPD patients, subjects with cough and sputum, and healthy smokers and nonsmokers.
According to the company, MIV-247, which is also entering non-clinical development, is a potent and highly selective inhibitor of cathepsin S, an enzyme shown to be important for the maintenance of the neuropathic pain state, through its action in releasing fractalkine (a pro-inflammatory protein) in areas of the spinal cord important for pain sensation.
Celera's cathepsin S inhibitor, CRA-028129, entered a Phase I trial in September 2005 in a single center study being conducted at the Christchurch Clinical Studies Trust (CSST) in Christchurch, New Zealand.
The acquisition of the Cathepsin S project is consistent with Medivir's ambition to enhance the commercial potential of our protease inhibitor portfolio.
We're pleased with the progress we've made in advancing our cathepsin S inhibitor through to this clinical development stage as a potential new treatment for psoriasis.
The most recent milestone payment recognizes selection of Celera Cathepsin S inhibitor compounds as Early Development Candidates (EDC) for inflammation and autoimmune diseases.
Cathepsin S is a protease (protein degrading enzyme) that plays a significant role in the activation of certain immune responses.
Cathepsin S is a protease enzyme that plays a central role in the initiation of an immune response.
The achievement represents the third in a series of research milestone criteria that precede selection of individual Cathepsin S inhibitors for development as drugs for inflammation and autoimmune disease, including rheumatoid arthritis, asthma, atherosclerosis, COPD and multiple sclerosis.
Senior Vice President, Research and Preclinical Development, and Chief Technical Officer, indicated that both the Merck Cathepsin K and the Aventis Cathepsin S programs were moving toward the nomination of IND candidates in the next several months.
Nasdaq:AXPH) announced today the achievement of an important research milestone in its collaboration with Aventis (NYSE:AVE) on Cathepsin S, an enzyme believed to play a critical role in asthma.